AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02721706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CIPA nutritional screening tool
Description: The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h \<50%, serum albumin \<3 g/dl, body mass index \<18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
Study NCT04778306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Laser Surgery
Description: Remove of the laryngeal tumour via diode laser
Study NCT01629576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: economic incentive
Description: economic incentive for weight loss
Study NCT04424966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infigratinib
Description: The Phase 0 study will include treatment of recurrent high-grade glioma participants with 125 mg of infigratinib 7 days prior to surgical resection. Participants with tumors demonstrating PK-response will continue treatment with the same dose continuously for 21 days in 28-day cycles after surgery.
Study NCT05530473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: capsular tension ring
Description: To insert a capsular tension ring during the cataract surgery
Study NCT00775528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase Delayed Release
Description: 3,000, 6,000 and 12,000 unit Lipase Capsules
Study NCT00117741 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
Study NCT00117741 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Drug Counseling
Description: Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
Study NCT02958852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Study NCT02958852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole and atorvastatin
Study NCT02958852 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fulvestrant
Description: Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
Study NCT02775539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron
Description: Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
Study NCT02775539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02139618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methyl Aminolevulinate (MAL)
Study NCT02139618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03093935 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StimRouter Neuromodulation System
Description: The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
Study NCT01657084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CDA Mask
Description: The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
Study NCT01657084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dummy mask
Description: The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
Study NCT02985619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin] (IVB-I)
Description: 0,05ml intravitreal injection
Study NCT02985619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide 10mg/mL (IVT-II)
Description: 0,03ml intravitreal injection
Study NCT02985619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab Injection [Avastin] (IVB-III)
Description: 0,05ml intravitreal injection
Study NCT03844724 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ZENFlow™ Drug-eluting PTA Balloon Dilatation Catheter
Description: Digital subtraction angiography（DSA）
Study NCT03844724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Balloon Dilatation Catheter
Description: Digital subtraction angiography（DSA）
Study NCT01976728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin acetate subcutaneous (SC) 10 μg/pulse as a fixed dose, administered via. OmniPod pump
Study NCT01976728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin acetate SC 15 μg/pulse as a fixed dose, administered via. OmniPod pump
Study NCT01976728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin acetate SC 20 μg/pulse as a fixed dose, administered via. OmniPod pump
Study NCT01976728 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (SC 10, 15, or 20 μg/pulse as a fixed dose, administered via. OmniPod pump)
Study NCT04025138 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular tests in isometric mode
Description: Protocol for neuromuscular tests in isometric mode will be assessed by the composite of these measures :~* Voluntary maximum forces plantar flexors and knee extensors~* Electrically evoked forces~* ElectroMyoGraphic activity (EMG)~* Three-Modality Evoked Potentials (TMEPs)
Study NCT04025138 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Measure of supraspinal activation level and cortical excitation by Transcranial Magnetic Stimulation (TMS).
Study NCT01300637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
Study NCT01300637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identical-appearing pill of placebo
Study NCT04431934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PROBIOTIC
Description: Participants assigned to the probiotic arm will receive 2 sachets of Vivomixx® dissolved in 50 L of warm water (according to the manufacturer indications) every 12 h orally or through a nasogastric tube (in this case the tube will be flushed with 50 mL of water after the administration). The probiotic will be started 24 h after the last dose of NAA and will be administered for 14 consecutive days. Each sachet of Vivomixx® contains a combination of 4 Lactobacillus (L. paracasei 24733, L. acidophilus 24735, L. delbrueckii ssp bulgaricus 24734, L. plantarum 24730), 3 Bifidobacteria (B. brief 24732, B. longum 24736, B. infantis 24737), and Streptococcus thermophilus 24731 at a concentration of 450 billion (45x1010) live lyophilized bacteria per sachet.
Study NCT04431934 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: FMT REGIMEN
Description: The FMT preparation will be administered as 2 doses, once a week, of 14-17 capsules per dose. Each dose (14-17 capsules) will contain the fecal microbiota equivalent to 50 gr of stools from a healthy donor. If the patient is carrying a nasogastric tube, the content of capsules will be decapsulized (\~27 gr of powder), diluted in 50 mL of water and passed through it, followed by the administration of 50 mL of water to flush the tube. The first dose will be administered 24 h after the last dose of NAA and the second dose one week later. Whenever possible, the two doses of FMT will be originated from the same donor. According to our data done by flow cytometry and bacterial culture in three replicates, each absorbate capsule contains approximately 1.12x1010 live bacteria.
Study NCT03221036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab IV
Description: Vedolizumab IV infusion
Study NCT03221036 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo IV infusion
Study NCT04083235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Irinotecan liposome injection is irinotecan in the form of the sucrosofate salt, encapsulated in liposomes for i.v. infusion. It is supplied in sterile, single-use vials containing 10 mL of irinotecan liposome injection at a concentration of 4.3 mg/mL free base equivalent (FBE).
Study NCT04083235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin injection, USP is supplied in single-dose vials containing 50 mg, 100 mg or 200 mg of oxaliplatin as a sterile, preservative-free, aqueous solution at a concentration of 5 mg/mL.
Study NCT04083235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: Fluorouracil injection, USP is a colorless to faint yellow, aqueous, sterile, nonpyrogenic injectable solution available in 50 mL and 100 mL pharmacy bulk package. Each mL contains 50 mg fluorouracil in water for injection, USP.
Study NCT04083235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin Calcium for Injection is supplied in vials ranging from 50-500 mg and available as an injectable solution or lyophilized powder for reconstitution.
Study NCT04083235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is a lyophilised powder containing 100 or 250 mg of paclitaxel formulated as albumin-bound particles in single-use vials for re-constitution. Each mL of the reconstituted formulation will contain 5 mg/mL paclitaxel.
Study NCT04083235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine for injection is a lyophilised powder for solution for infusion, with each single use vial containing 200 mg, 1 g or 2 g of gemcitabine.
Study NCT01342666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato consumption
Description: Daily consumption of 300g of uncooked roma tomatoes during one month.
Study NCT03355495 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonoscopy - Position Change
Description: Colonoscopy is the gold standard for detecting precancerous lesions. We are proposing that changing positions will provide better visualization for detecting such lesions. We will test our intervention of patients positioned in the Right Lateral Decubitus Position to the gold standard of Left Lateral Decubitus Positioning, hypothesizing better visualization in the right lateral decubitus position.
Study NCT03284411 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Programming
Study NCT03155152 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DECT
Description: The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
Study NCT03155152 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIIT
Description: The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
Study NCT04074148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education Program
Description: An educational lifestyle modification program, offering 4 sessions of 30 minutes theory and 30 minutes practice each, total duration 6 months
Study NCT04074148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Education brochure
Description: An educational lifestyle modification brochure
Study NCT04300816 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT for Uncertainty Tolerance
Description: Participants work one-on-one with an interventionist. Treatment sessions focus on understanding the difference between the controllable and uncontrollable aspects of MS, ability to tolerate not knowing exactly what the future will hold, setting personal goals for what accepting what MS will look like, and finding ways to live in conjunction with personal values despite the MS diagnosis.
Study NCT04300816 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CBT
Description: Participants work one-on-one with an interventionist. Treatment sessions focus on goal setting, positive activities, identifying and challenging unhelpful thoughts, and bolstering social support.
Study NCT02931123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lattulose and rifaximine
Study NCT03265210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELIEF
Description: A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
Study NCT03911245 — intervention group
Intervention type: OTHER
Intervention: Retrospective study. Analyze of data in medical records
Description: Retrospective study. Analyze of data in medical records
Study NCT03015974 — intervention group
Intervention type: DRUG
Intervention: Corticosteroid
Study NCT01342666 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cucumber consumption
Description: Daily consumption of 300g of cucumber.
Study NCT04818710 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: skin incision with a scalpel
Description: A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 1 (skin incision with a scalpel)
Study NCT04818710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: skin incision with diathermy
Description: A Pfannenstiel skin incision was done through the subcutaneous tissue, rectus sheath and dissected from rectus muscle until peritoneum was visualized.~group 2 (skin incision with diathermy)
Study NCT00414310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 50 mg/kg orally daily for 7 days
Study NCT03209544 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Description: The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, \& Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
Study NCT00333268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next Generation Ophthalmic Irrigating Solution (NGOIS)
Description: Volume sufficient to irrigate adequately during cataract surgery
Study NCT00333268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BSS Plus
Description: Volume sufficient to irrigate adequately during cataract surgery
Study NCT04422665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Single-legged resistance exercise
Study NCT04177056 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients will received a single fraction of 15-20 Gy to bone metastases causing pain. Planning and delivery will be conducted using a volumetric modulated arc therapy (VMAT) approach on the Varian TrueBeam platform. Patients will be CT simulated, with vac-lock immobilization. Use of 4-dimensional CT will be dependent on the area being treated. Daily image guidance will be performed using cone beam CT aligning to relevant bony anatomy.
Study NCT04008433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Advanced intravenous injection of lidocaine before the propofol injection
Study NCT02222012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: single channel Multiway Coil®
Description: During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
Study NCT02222012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two channels Multiway stimulator coil® (Brainsway Ltd.)
Description: During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.~10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)~1 Hz protocol:~1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks).
Study NCT03000816 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with 1-4 metastases located in less than 2 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
Study NCT03977727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fiasp®
Description: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
Study NCT03977727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog®
Description: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system
Study NCT03977727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670G hybrid closed loop continuous subcutaneous insulin infusion system
Description: CSII
Study NCT00374153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Online personal feedback report
Study NCT00374153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview with Feedback
Description: In-person Motivational Interview with personal feedback report
Study NCT00374153 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: In-person Motivational Interview only (without a personal feedback report)
Study NCT03252704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistant starch (high fiber muffin top)
Description: Muffin top contained 11 g of fiber per portion
Study NCT03252704 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control (low fiber muffin top)
Description: Muffin top contained 1 g of fiber per portion
Study NCT03072719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
Study NCT03072719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
Study NCT01199263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01199263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT01199263 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pelareorep
Description: Given IV
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_80 mg
Description: PBF-509: 80 mg, PO, twice daily (BID)
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_160 mg
Description: PBF-509: 160 mg, PO, twice daily (BID)
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_320 mg
Description: PBF-509: 320 mg, PO, twice daily (BID)
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509_640 mg
Description: PBF-509: 640 mg, PO, twice daily (BID)
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo PBF-509 (160 mg) + PDR001
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo PBF-509 (320 mg) + PDR001
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combo PBF-509 (640 mg) + PDR001
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Study NCT03015974 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP2D (PBF-509+PDR001)_immuno naïve
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
Study NCT02403193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: RP2D (PBF-509+PDR001)_immuno treated
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally